Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD53 | P19397 | Leukocyte surface antigen CD53 (Cell surface glycoprotein CD53) (Tetraspanin-25) (Tspan-25) (CD antigen CD53) | CD markersPredicted membrane proteinsTransporters | 4 | Fusion and delivery mediationImmune mediation | 9 | 0.38 | |||
| CXCR1 | P25024 | C-X-C chemokine receptor type 1 (CXC-R1) (CXCR-1) (CDw128a) (High affinity interleukin-8 receptor A) (IL-8R A) (IL-8 receptor type 1) (CD antigen CD181) | Cancer-related genesCD markersG-protein coupled receptors | 7 | Chronic obstructive pulmonary diseaseGoutIndeterminate colitis | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 9 | 0.38 | ||
| SC6A6 | P31641 | Sodium- and chloride-dependent taurine transporter (Solute carrier family 6 member 6) (Taurine transporter) (TauT) | Disease related genesMetabolic proteinsPotential drug targets | 12 | Clinical-translation mediationFusion and delivery mediation | 9 | 0.38 | |||
| CLN3 | Q13286 | Battenin (Batten disease protein) (Protein CLN3) | Disease related genesHuman disease related genesPotential drug targets | 6 | Lysosomal disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 8 | 0.38 | ||
| CNNM3 | Q8NE01 | Metal transporter CNNM3 (Ancient conserved domain-containing protein 3) (Cyclin-M3) | Predicted membrane proteinsTransporters | 4 | Metabolism mediation | 8 | 0.38 | |||
| CR2 | P20023 | Complement receptor type 2 (Cr2) (Complement C3d receptor) (Epstein-Barr virus receptor) (EBV receptor) (CD antigen CD21) | CD markersDisease related genesHuman disease related genes | 1 | Immune mediation | 8 | 0.38 | |||
| PEAR1 | Q5VY43 | Platelet endothelial aggregation receptor 1 (hPEAR1) (Multiple epidermal growth factor-like domains protein 12) (Multiple EGF-like domains protein 12) | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Immune mediationMetabolism mediationReceptor-signaling mediation | 8 | 0.38 | |||
| ANPRB | P20594 | Atrial natriuretic peptide receptor 2 (EC 4.6.1.2) (Atrial natriuretic peptide receptor type B) (ANP-B) (ANPR-B) (NPR-B) (Guanylate cyclase B) (GC-B) | 1 | Immune mediationReceptor-signaling mediation | 7 | 0.38 | ||||
| BASI | P35613 | Basigin (5F7) (Collagenase stimulatory factor) (Extracellular matrix metalloproteinase inducer) (EMMPRIN) (Hepatoma-associated antigen) (HAb18G) (Leukocyte activation antigen M6) (OK blood group antigen) (Tumor cell-derived collagenase stimulatory factor) (TCSF) (CD antigen CD147) | Blood group antigen proteinsCD markersPredicted intracellular proteins | 1 | Graft-versus-host diseaseLiver cancerCOVID-19 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 7 | 0.38 | ||
| CD19 | P15391 | B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19) | CD markersDisease related genesFDA approved drug targets | 1 | Acute myeloid leukaemiaB-cell lymphomaDiabetes mellitus | Clinical-translation mediationFusion and delivery mediationImmune mediation | 7 | 0.38 | ||
| ROR2 | Q01974 | Tyrosine-protein kinase transmembrane receptor ROR2 (EC 2.7.10.1) (Neurotrophic tyrosine kinase, receptor-related 2) | 1 | Metastatic lymph node neoplasmRenal cell carcinoma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 7 | 0.38 | |||
| S12A9 | Q9BXP2 | Solute carrier family 12 member 9 (Cation-chloride cotransporter 6) (hCCC6) (Cation-chloride cotransporter-interacting protein 1) (CCC-interacting protein 1) (hCIP1) (Potassium-chloride transporter 9) (WO3.3) | Predicted membrane proteinsTransporters | 12 | Fusion and delivery mediation | 7 | 0.38 | |||
| TRPC6 | Q9Y210 | Short transient receptor potential channel 6 (TrpC6) (Transient receptor protein 6) (TRP-6) | Disease related genesHuman disease related genesPlasma proteins | 6 | Fusion and delivery mediationImmune mediationMetabolism mediation | 7 | 0.38 | |||
| CADM3 | Q8N126 | Cell adhesion molecule 3 (Brain immunoglobulin receptor) (Immunoglobulin superfamily member 4B) (IgSF4B) (Nectin-like protein 1) (NECL-1) (Synaptic cell adhesion molecule 3) (SynCAM3) (TSLC1-like protein 1) (TSLL1) | Disease related genesHuman disease related genesPredicted intracellular proteins | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 6 | 0.38 | |||
| CRIM1 | Q9NZV1 | Cysteine-rich motor neuron 1 protein (CRIM-1) (Cysteine-rich repeat-containing protein S52) [Cleaved into: Processed cysteine-rich motor neuron 1 protein] | Predicted intracellular proteinsPredicted membrane proteinsTransporters | 1 | Other mediation | 6 | 0.38 | |||
| ENPP3 | O14638 | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (E-NPP 3) (NPP3) (Alkaline phosphodiesterase I) (EC 3.1.4.1) (Dinucleoside polyphosphatase) (EC 3.6.1.-) (Nucleotide diphosphatase) (Nucleotide pyrophosphatase) (NPPase) (EC 3.6.1.9) (Phosphodiesterase I beta) (PD-Ibeta) (Phosphodiesterase I/nucleotide pyrophosphatase 3) (CD antigen CD203c) | CD markersEnzymesMetabolic proteins | 1 | Renal cell carcinoma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 6 | 0.38 | ||
| EPHB3 | P54753 | Ephrin type-B receptor 3 (EC 2.7.10.1) (EPH-like tyrosine kinase 2) (EPH-like kinase 2) (Embryonic kinase 2) (EK2) (hEK2) (Tyrosine-protein kinase TYRO6) | Cancer-related genesEnzymesPredicted membrane proteins | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 6 | 0.38 | |||
| FCER2 | P06734 | Low affinity immunoglobulin epsilon Fc receptor (BLAST-2) (C-type lectin domain family 4 member J) (Fc-epsilon-RII) (Immunoglobulin E-binding factor) (Lymphocyte IgE receptor) (CD antigen CD23) [Cleaved into: Low affinity immunoglobulin epsilon Fc receptor membrane-bound form; Low affinity immunoglobulin epsilon Fc receptor soluble form] | Cancer-related genesCD markersPredicted intracellular proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 6 | 0.38 | |||
| GP107 | Q5VW38 | Protein GPR107 (Lung seven transmembrane receptor 1) | Predicted membrane proteinsTransporters | 7 | Adhesion and uptake mediationFusion and delivery mediation | 6 | 0.38 | |||
| LRC4B | Q9NT99 | Leucine-rich repeat-containing protein 4B (Netrin-G3 ligand) (NGL-3) | Predicted intracellular proteinsPredicted membrane proteinsTransporters | 1 | Adhesion and uptake mediation | 6 | 0.38 | |||
| LRC8C | Q8TDW0 | Volume-regulated anion channel subunit LRRC8C (Factor for adipocyte differentiation 158) (Leucine-rich repeat-containing protein 8C) | Predicted membrane proteinsTransporters | 4 | Fusion and delivery mediation | 6 | 0.38 | |||
| PCD18 | Q9HCL0 | Protocadherin-18 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediation | 6 | 0.38 | |||
| RHDF2 | Q6PJF5 | Inactive rhomboid protein 2 (iRhom2) (Rhomboid 5 homolog 2) (Rhomboid family member 2) (Rhomboid veinlet-like protein 5) (Rhomboid veinlet-like protein 6) | Disease related genesEnzymesPotential drug targets | 7 | Skin diseaseSolid tumour/cancer | Clinical-translation mediationFusion and delivery mediationImmune mediation | 6 | 0.38 | ||
| CD33 | P20138 | Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33) | CD markersFDA approved drug targetsPlasma proteins | 1 | Acute myeloid leukaemiaAlzheimer diseaseBCR-ABL1-negative chronic myeloid leukaemia | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.38 | ||
| CRLF2 | Q9HC73 | Cytokine receptor-like factor 2 (Cytokine receptor-like 2) (IL-XR) (Thymic stromal lymphopoietin protein receptor) (TSLP receptor) | 1 | Asthma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.38 |